This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Illinois. Active years: 2019-2021.
Company Filing History:
2 out of 3,690 
2 out of 2,421 
Years Active: 2019-2021
Title: The Innovations of Boris Garnier
Introduction
Boris Garnier is a notable inventor based in Châtenay-Malabry, France. He has made significant contributions to the field of biochemistry, particularly in the development of peptide analogs for therapeutic applications. With a total of 2 patents, his work focuses on addressing diseases mediated by the CCR3 chemokine receptor.
Latest Patents
Garnier's latest patents include a peptide inhibition of CCR3-mediated diseases or conditions. This invention involves a C-C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism. The peptide binds to and inhibits ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3. This method is designed to treat, prevent, or ameliorate symptoms associated with eosinophil- or CCR3-mediated diseases or conditions.
Career Highlights
Throughout his career, Boris Garnier has worked with prestigious institutions, including the University of Illinois and the United States Department of Health and Human Services. His research has contributed to advancements in understanding and treating various medical conditions.
Collaborations
Garnier has collaborated with notable professionals in his field, including Steven Jules Ackerman and Fan Gao Laffey. These partnerships have enhanced the scope and impact of his research.
Conclusion
Boris Garnier's innovative work in peptide analogs showcases his commitment to advancing medical science. His contributions are significant in the ongoing efforts to develop effective treatments for CCR3-mediated diseases.